DBI: Deutsche Biotech Innovativ AG - Summary | Jitta

Deutsche Biotech Innovativ AG

DEU:DBI

Notice
Stock data is unavailable or the company’s delisted.
Price
€1.11
Loss Chance
54.3%
2.10JITTA SCORE
100.00%Over Jitta Line
Jitta Ranking
Sorry, the data is not yet available for this stock.
HISTORICAL JITTA SCORE
Jitta Factors
Growth Opportunity (21)
Recent Business Performance (28)
Financial Strength (35)
Return to Shareholders (0)
Competitive Advantage (23)
Jitta Signs
Recent Business PerformanceEarning Growth Last Year
Recent IPOLess than 3 years
CapExVery High
Key Stats
Jitta Score
Jitta Line
2.10
100.00%
2.46
> 1,000%
2.46
> 1,000%
2.17
26.55%
0.29
100.00%
3.41
> 1,000%
COMPANY DESCRIPTION
Deutsche Biotech Innovativ AG operates as a biotechnology company in Germany. The company develops Adrecizumab, an antibody-based therapy that has completed the Phase I/II clinical trial for the treatment of septic shock. It also focuses on the development of various drugs for the treatment of solid tumor, organ failure, rosacea, neurodermatitis, pharyngitis, and Alzheimer's diseases. The company was formerly known as Venetus Beteiligungen AG and changed its name to Deutsche Biotech Innovativ AG in August 2014. Deutsche Biotech Innovativ AG was founded in 2009 and is based in Hennigsdorf, Germany.